|Articles|September 8, 2005

175 CDER-Registered Facilities in Katrina Disaster Area

175 CDER-Registered Facilities in Katrina Disaster Area

has cross-referenced a list of zip codes for FEMA-designated Gulf Coast disaster areas with a database of manufacturing facilities registered with the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER).

The comparison yielded a list of 175 facilities operated by 120 organizations. Of these facilities, 92 were in Louisiana, 65 in Mississippi, and 18 in Alabama.

Most of the locations are operated by medical gas producers (49) or providers (60, typically regional health chains, home health agencies, respiratory therapy companies, and medical supply houses).

Of the remainder, only a handful could be identified as fine chemical producers (11) or pharmaceutical companies or contract manufacturers (12).

Despite the widespread damage and flooding, some facilities, especially those at the edges of the disaster area, remain in operation.

–Douglas McCormick

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.